Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

The OG OJ: Classic Aussie juice range gets a shake up

  • In News
  • September 20, 2021
  • Samantha Freidin
The OG OJ: Classic Aussie juice range gets a shake up

Juice- both a Saturday morning staple and an adjunct to that near toxic tequila you got for your 18th. 

Fruity beverage mogul Food Revolution Group (ASX: FOD) is helping keep those crappy tequila brands in the green with the expansion of their range of juices. 

The Company plans to expand three products throughout the Coles and Woolworths networks.

Their ‘OG’ product, the easily recognisable Black Label range has maintained strong market performance with double digit sales growth thanks to customer loyalty stemming from brand awareness and recognition.

Their new extended Black Label range will include a 50% less sugar orange and apple variety as well as a new apple range. Products are expected to be in the market by the end of this month and have been accepted for sale in both Coles and Woolworths. 

The Company’s foray into single packaged beverages has been well received with both their Juice Lab products earmarked for expansion. 

Since launch, the Juice Lab Wellness Shots have outperformed sales expectations, the brand now holds a 70% share of the growing ‘functional shots’ category. Society’s ever growing health consciousness has prompted savvy buyers at Coles to increase the distribution of the range from 477 stores to over 1000 stores nationwide.

Three flavours of the Juice Lab Carbonated Wellness Cans are due to be introduced to Coles and Woolworths stores as a low sugar alternative for those who aren’t that into kombucha, addressing a gap in the market. Seeking a slice of the $3 billion dollar carbonated beverage market, Juice Lab’s canned drinks are expected on shelves from late Q1 FY22 and will run across summer.

CEO of Food Revolution Group, Steven Cail said: “We are delighted with the strong growth and consumer demand we have seen for our Juice Lab Wellness Shots. Wellness and functional beverages are a growing segment in the Australian beverage sector and our Juice Lab range continues to grow market share. The increased distribution network through major retailers, such as Coles and Woolworths, is a reflection of consumer demand and our continued focus on product quality. We will continue to drive our support behind this fantastic product and we anticipate the range to contribute to our ongoing revenue growth.”

“With new and increasing product ranges and strong demand for our core Original Juice product, the Company is well positioned to continue to drive operational and financial improvement into FY22 and beyond.”

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.